Avenue Therapeutics, Inc. (ATXI) shareholders
Close on Oct 16, 2026Market cap $1.42MP/E –Yield –
Ownership
Institutional holdings as of Mar 31, 2025, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fortress Biotech, Inc. | 439,955 | 13.40% | 13D (active) amendment | Jan 2, 2026 |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 7 | 0M | 0M |
| Q4 2024 | 7 | 0M | 5.8% | 3 / 3 | 1 / 4 | 0M | 0M |
| Q3 2024 | 8 | 0M | 6.0% | 1 / 5 | 1 / 1 | 0M | 0M |
| Q2 2024 | 9 | 0M | 3.5% | 9 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Neil Herskowitz | Director | 97 | 0.00% | Dec 3, 2024 |
| Fortress Biotech, Inc. | 10% owner | 439,733 | 13.35% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Fortress Biotech, Inc. 10% owner | Jan 2, 2026 | Award | +111,209 | – | – | 439,733 |
| Fortress Biotech, Inc. 10% owner | Mar 31, 2025 | Award | +33,724 | – | – | 328,524 |
| Neil Herskowitz Director | Dec 2, 2024 | Sale | −23 | $2.00 | $46 | 97 |
| Jay D. Kranzler Director | Nov 5, 2024 | Sale | −61 | $2.24 | $137 | 559 |
| Jay D. Kranzler Director | Sep 30, 2024 | Buy | +497 | $2.50 | $1.24K | 620 |
| Jay D. Kranzler Director | Sep 27, 2024 | Buy | +3 | $2.40 | $7 | 123 |
| David Jin Interim PFO and COO | Sep 23, 2024 | Award | +65,000 | – | – | 65,000 |
| Alexandra MacLean Chief Executive Officer, Director | Sep 23, 2024 | Award | +170,000 | – | – | 170,000 |
| Fortress Biotech, Inc. 10% owner | Apr 16, 2024 | Award | +413,507 | – | – | 3,547,393 |
| Fortress Biotech, Inc. 10% owner | Jan 2, 2024 | Award | +2,101,496 | – | – | 3,133,886 |
| Robert L. Davidow 10% owner | Dec 11, 2023 | Sale | −264,000 | $0.14 | $36.96K | 681,000 |
| Robert L. Davidow 10% owner | Dec 11, 2023 | Sale | −20,000 | $0.14 | $2.80K | 80,000 |
| Robert L. Davidow 10% owner | Dec 11, 2023 | Sale | −18,000 | $0.15 | $2.70K | 22,000 |
| Robert L. Davidow 10% owner | Dec 11, 2023 | Sale | −61,000 | $0.14 | $8.54K | 74,000 |
| Robert L. Davidow 10% owner | Dec 11, 2023 | Sale | −126,000 | $0.14 | $17.64K | 215,800 |
| Robert L. Davidow 10% owner | Dec 11, 2023 | Sale | −128,000 | $0.14 | $17.92K | 147,000 |
| Fortress Biotech, Inc. 10% owner | Sep 8, 2023 | Buy | +418,410 | $0.72 | $301.26K | 1,032,390 |
| Lindsay A. Rosenwald Md Director | Sep 8, 2023 | Buy | +348,675 | $0.72 | $251.05K | 354,318 |
| Fortress Biotech, Inc. 10% owner | Mar 31, 2023 | Award | +52,419 | – | – | 613,980 |
| Fortress Biotech, Inc. 10% owner | Jan 3, 2023 | Award | +231,316 | – | – | 561,561 |
| Fortress Biotech, Inc. 10% owner | Dec 31, 2022 | Award | +90,909 | – | – | 330,245 |
| InvaGen Pharmaceuticals, Inc. 10% owner | Oct 11, 2022 | Sale | −388,888 | $7.71 | $3.00M | 0 |
| Jay D. Kranzler Director | Dec 17, 2021 | Award | +49,020 | – | – | 113,683 |
| Jay D. Kranzler Director | Dec 17, 2021 | Award | +20,000 | – | – | 133,683 |
| Curtis Gale Oltmans Director | Dec 17, 2021 | Award | +49,020 | – | – | 49,020 |
| Neil Herskowitz Director | Dec 17, 2021 | Award | +20,000 | – | – | 183,744 |
| Neil Herskowitz Director | Dec 17, 2021 | Award | +49,020 | – | – | 163,744 |
| Joseph Walter Vazzano Chief Financial Officer | Dec 17, 2021 | Award | +100,505 | – | – | 165,757 |
| Lucy Lu President, CEO, Director | Dec 17, 2021 | Award | +411,616 | – | – | 748,949 |
| Joseph Walter Vazzano Chief Financial Officer | Sep 15, 2021 | Sale | −7,160 | $1.62 | $11.60K | 65,252 |
| Neil Herskowitz Director | May 6, 2021 | Buy | +2,500 | $3.99 | $9.98K | 134,724 |
| Joseph Walter Vazzano Chief Financial Officer | Aug 20, 2020 | Sale | −3,840 | $12.13 | $46.58K | 57,412 |
| Jay D. Kranzler Director | Jun 16, 2020 | Award | +10,000 | – | – | 84,663 |
| Neil Herskowitz Director | Jun 16, 2020 | Award | +10,000 | – | – | 132,224 |
| Joseph Walter Vazzano Chief Financial Officer | Mar 10, 2020 | Buy | +1,889 | $7.94 | $15.00K | 61,252 |
| Joseph Walter Vazzano Chief Financial Officer | Mar 9, 2020 | Buy | +1,400 | $7.99 | $11.19K | 59,263 |
| Joseph Walter Vazzano Chief Financial Officer | Mar 9, 2020 | Buy | +100 | $7.97 | $797 | 59,363 |
| Neil Herskowitz Director | Feb 27, 2020 | Buy | +2,400 | $8.20 | $19.68K | 122,224 |
| Neil Herskowitz Director | Feb 26, 2020 | Buy | +161 | $8.73 | $1.41K | 119,824 |
| Joseph Walter Vazzano Chief Financial Officer | Feb 25, 2020 | Buy | +1,200 | $9.09 | $10.91K | 57,863 |
| Neil Herskowitz Director | Feb 25, 2020 | Buy | +10,000 | $9.31 | $93.10K | 119,663 |
| Elizabeth Garrett Ingram Director | Sep 12, 2019 | Buy | +16,000 | $6.27 | $100.32K | 16,000 |
| Neil Herskowitz Director | Aug 27, 2019 | Award | +10,000 | – | – | 109,663 |
| Jay D. Kranzler Director | Aug 27, 2019 | Award | +10,000 | – | – | 74,663 |
| Joseph Walter Vazzano Chief Financial Officer | Aug 9, 2019 | Sale | −2,375 | $5.56 | $13.20K | 56,663 |
| Joseph Walter Vazzano Chief Financial Officer | Aug 8, 2019 | Sale | −2,313 | $5.62 | $13.00K | 59,038 |
| Neil Herskowitz Director | Jun 18, 2019 | Buy | +2,000 | $5.83 | $11.66K | 99,663 |
| Neil Herskowitz Director | Jun 17, 2019 | Buy | +3,000 | $5.88 | $17.64K | 97,663 |
| Neil Herskowitz Director | Apr 15, 2019 | Buy | +1,000 | $4.52 | $4.52K | 94,663 |
| Neil Herskowitz Director | Mar 29, 2019 | Buy | +1,400 | $5.11 | $7.15K | 93,663 |
| Neil Herskowitz Director | Mar 28, 2019 | Buy | +600 | $5.11 | $3.07K | 92,263 |
| Neil Herskowitz Director | Feb 25, 2019 | Buy | +5,000 | $5.46 | $27.30K | 91,663 |
| Neil Herskowitz Director | Feb 5, 2019 | Buy | +1,850 | $5.77 | $10.67K | 86,663 |
| Neil Herskowitz Director | Feb 4, 2019 | Buy | +7,000 | $5.91 | $41.37K | 84,813 |
| Neil Herskowitz Director | Jan 30, 2019 | Buy | +650 | $5.91 | $3.84K | 77,813 |
| Neil Herskowitz Director | Jan 29, 2019 | Buy | +8,553 | $5.91 | $50.55K | 77,163 |
| Neil Herskowitz Director | Jan 28, 2019 | Buy | +1,447 | $5.84 | $8.45K | 68,610 |
| Jeffrey Paley Director | Dec 10, 2018 | Buy | +5,000 | $4.76 | $23.80K | 79,663 |
| Jeffrey Paley Director | Dec 3, 2018 | Buy | +10,000 | $5.48 | $54.80K | 74,663 |
| Jeffrey Paley Director | Aug 7, 2018 | Gift | +14,663 | – | – | 64,663 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Avenue Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?